HPGC Renmintongtai Pharmaceutical Corp (600829) - Total Assets
Based on the latest financial reports, HPGC Renmintongtai Pharmaceutical Corp (600829) holds total assets worth CN¥7.35 Billion CNY (≈ $1.08 Billion USD) as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
HPGC Renmintongtai Pharmaceutical Corp - Total Assets Trend (1994–2025)
This chart illustrates how HPGC Renmintongtai Pharmaceutical Corp's total assets have evolved over time, based on quarterly financial data. Also see HPGC Renmintongtai Pharmaceutical Corp (600829) market capitalisation for the company's overall valuation and market capitalisation.
HPGC Renmintongtai Pharmaceutical Corp - Asset Composition Analysis
Current Asset Composition (December 2025)
HPGC Renmintongtai Pharmaceutical Corp's total assets of CN¥7.35 Billion consist of 93.3% current assets and 6.7% non-current assets. Review HPGC Renmintongtai Pharmaceutical Corp balance sheet liabilities to assess the company's total debt and financial obligations.
| Asset Category | Amount (CNY) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 17.2% |
| Accounts Receivable | CN¥3.85 Billion | 53.7% |
| Inventory | CN¥1.23 Billion | 17.2% |
| Property, Plant & Equipment | CN¥0.00 | 0.0% |
| Intangible Assets | CN¥26.34 Million | 0.4% |
| Goodwill | CN¥0.00 | 0.0% |
Asset Composition Trend (1994–2025)
This chart illustrates how HPGC Renmintongtai Pharmaceutical Corp's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See 600829 live share price for real-time trading data and today's change.
Key Asset Composition Facts
- Current vs. Non-Current Assets: HPGC Renmintongtai Pharmaceutical Corp's current assets represent 93.3% of total assets in 2025, an increase from 40.1% in 1994.
- Cash Position: Cash and equivalents constituted 17.2% of total assets in 2025, up from 0.0% in 1994.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 1994.
- Asset Diversification: The largest asset category is accounts receivable at 53.7% of total assets.
HPGC Renmintongtai Pharmaceutical Corp Competitors by Total Assets
Key competitors of HPGC Renmintongtai Pharmaceutical Corp based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Torrent Pharmaceuticals Limited
NSE:TORNTPHARM
|
India | Rs443.12 Billion |
|
Swedish Orphan Biovitrum AB (publ)
ST:SOBI
|
Sweden | Skr81.26 Billion |
|
Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt
F:RIG2
|
Germany | €1.60 Trillion |
|
Beijing Tongrentang Co Ltd
SHG:600085
|
China | CN¥29.95 Billion |
|
Shandong Buchang Pharmaceuticals Co Ltd
SHG:603858
|
China | CN¥19.57 Billion |
|
Shan Dong Dong-E E-Jiao Co Ltd
SHE:000423
|
China | CN¥12.75 Billion |
|
Harbin Pharmaceutical Group Co Ltd
SHG:600664
|
China | CN¥14.08 Billion |
|
Kangmei Pharmaceutical Co Ltd
SHG:600518
|
China | CN¥13.68 Billion |
HPGC Renmintongtai Pharmaceutical Corp - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.66 | 1.63 | 1.44 |
| Quick Ratio | 1.35 | 1.38 | 1.22 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CN¥2.72 Billion | CN¥2.60 Billion | CN¥1.72 Billion |
HPGC Renmintongtai Pharmaceutical Corp - Advanced Valuation Insights
This section examines the relationship between HPGC Renmintongtai Pharmaceutical Corp's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.86 |
| Latest Market Cap to Assets Ratio | 0.12 |
| Asset Growth Rate (YoY) | 0.1% |
| Total Assets | CN¥7.17 Billion |
| Market Capitalization | $857.04 Million USD |
Valuation Analysis
Below Book Valuation: The market values HPGC Renmintongtai Pharmaceutical Corp's assets below their book value (0.12x), which may indicate investor concerns about asset quality or future growth.
Positive Asset Growth: HPGC Renmintongtai Pharmaceutical Corp's assets grew by 0.1% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for HPGC Renmintongtai Pharmaceutical Corp (1994–2025)
The table below shows the annual total assets of HPGC Renmintongtai Pharmaceutical Corp from 1994 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | CN¥7.17 Billion ≈ $1.05 Billion |
+0.12% |
| 2024-12-31 | CN¥7.17 Billion ≈ $1.05 Billion |
-3.50% |
| 2023-12-31 | CN¥7.43 Billion ≈ $1.09 Billion |
+5.21% |
| 2022-12-31 | CN¥7.06 Billion ≈ $1.03 Billion |
+4.60% |
| 2021-12-31 | CN¥6.75 Billion ≈ $987.44 Million |
+12.56% |
| 2020-12-31 | CN¥6.00 Billion ≈ $877.28 Million |
+8.07% |
| 2019-12-31 | CN¥5.55 Billion ≈ $811.75 Million |
+25.72% |
| 2018-12-31 | CN¥4.41 Billion ≈ $645.67 Million |
-8.86% |
| 2017-12-31 | CN¥4.84 Billion ≈ $708.45 Million |
+0.65% |
| 2016-12-31 | CN¥4.81 Billion ≈ $703.87 Million |
+13.65% |
| 2015-12-31 | CN¥4.23 Billion ≈ $619.35 Million |
+28.97% |
| 2014-12-31 | CN¥3.28 Billion ≈ $480.22 Million |
-11.33% |
| 2013-12-31 | CN¥3.70 Billion ≈ $541.58 Million |
-8.65% |
| 2012-12-31 | CN¥4.05 Billion ≈ $592.86 Million |
+5.40% |
| 2011-12-31 | CN¥3.84 Billion ≈ $562.48 Million |
+15.74% |
| 2010-12-31 | CN¥3.32 Billion ≈ $485.97 Million |
+16.38% |
| 2009-12-31 | CN¥2.85 Billion ≈ $417.56 Million |
-2.09% |
| 2008-12-31 | CN¥2.91 Billion ≈ $426.49 Million |
+8.74% |
| 2007-12-31 | CN¥2.68 Billion ≈ $392.22 Million |
+19.69% |
| 2006-12-31 | CN¥2.24 Billion ≈ $327.69 Million |
+12.58% |
| 2005-12-31 | CN¥1.99 Billion ≈ $291.07 Million |
+6.46% |
| 2004-12-31 | CN¥1.87 Billion ≈ $273.41 Million |
+73.51% |
| 2003-12-31 | CN¥1.08 Billion ≈ $157.58 Million |
+15.80% |
| 2002-12-31 | CN¥929.89 Million ≈ $136.07 Million |
-3.21% |
| 2001-12-31 | CN¥960.70 Million ≈ $140.58 Million |
-4.04% |
| 2000-12-31 | CN¥1.00 Billion ≈ $146.49 Million |
+41.06% |
| 1999-12-31 | CN¥709.69 Million ≈ $103.85 Million |
+5.54% |
| 1998-12-31 | CN¥672.44 Million ≈ $98.40 Million |
+0.74% |
| 1997-12-31 | CN¥667.48 Million ≈ $97.67 Million |
+3.28% |
| 1996-12-31 | CN¥646.29 Million ≈ $94.57 Million |
+1.90% |
| 1995-12-31 | CN¥634.21 Million ≈ $92.81 Million |
+4.46% |
| 1994-12-31 | CN¥607.13 Million ≈ $88.84 Million |
-- |
About HPGC Renmintongtai Pharmaceutical Corp
HPGC Renmintongtai Pharmaceutical Corporation engages in the wholesale and retail of pharmaceutical products in China and internationally. The company offers Chinese and Western patent medicines, Chinese herbal medicines and slices, chemical preparations, antibiotics, biological products, biochemical drugs, medical devices, and health products, as well as tonic health, daily necessities, and cosm… Read more